CIK 0000886163 · Large accelerated filer
LIGAND PHARMACEUTICALS INC
Sign in to watch- Tickers
- LGND LGNDZ LGNXZ LGNYZ LGNZZ
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 770160744
- Phone
- 858-550-7500
- Business address
- 3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO, CA, 92121
- Former names
- LIGAND PHARMACEUTICALS
Securities
- LGND Common Stock Nasdaq
- LGNDZ Common stock OTC
- LGNXZ Common stock OTC
- LGNYZ Common stock OTC
- LGNZZ Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $6,585,411
- in 7 filings, $4.5M under 10b5-1 plans
Net −$6,585,411. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-04 | Espinoza Octavio Chief Financial Officer | Sale 10b5-1 | −699 | $198.71 | $139K | 34,386 |
| 2026-03-04 | Espinoza Octavio Chief Financial Officer | Sale 10b5-1 | −53 | $200.08 | $11K | 34,333 |
| 2026-03-04 | Espinoza Octavio Chief Financial Officer | Sale 10b5-1 | −698 | $201.09 | $140K | 33,635 |
| 2026-03-04 | Espinoza Octavio Chief Financial Officer | Sale 10b5-1 | −950 | $201.73 | $192K | 32,685 |
| 2026-03-04 | Espinoza Octavio Chief Financial Officer | Sale 10b5-1 | −697 | $202.79 | $141K | 31,988 |
| 2026-03-04 | Espinoza Octavio Chief Financial Officer | Sale 10b5-1 | −668 | $203.63 | $136K | 31,320 |
| 2026-03-04 | Espinoza Octavio Chief Financial Officer | Sale 10b5-1 | −743 | $204.74 | $152K | 30,577 |
| 2026-03-04 | Espinoza Octavio Chief Financial Officer | Sale 10b5-1 | −1,457 | $205.79 | $300K | 29,120 |
| 2026-03-04 | Espinoza Octavio Chief Financial Officer | Sale 10b5-1 | −1,588 | $206.89 | $329K | 27,532 |
| 2026-03-04 | Espinoza Octavio Chief Financial Officer | Sale 10b5-1 | −2,457 | $207.91 | $511K | 25,075 |
| 2026-03-04 | Espinoza Octavio Chief Financial Officer | Sale 10b5-1 | −3,413 | $208.80 | $713K | 21,662 |
| 2026-03-04 | Espinoza Octavio Chief Financial Officer | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −1,607 | 0 | ||
| 2026-03-04 | Espinoza Octavio Chief Financial Officer | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −466 | 0 | ||
| 2026-03-03 | Sabba Stephen L Director | Option exercise | +2,034 | $69.51 | $141K | 35,827 |
| 2026-03-03 | Sabba Stephen L Director | Sale | −2,034 | $201.50 | $410K | 33,793 |
| 2026-03-03 | Sabba Stephen L Director | Option exercise · Non- Qualified Stock Option (right to buy) | −2,034 | 0 | ||
| 2026-03-02 | Espinoza Octavio Chief Financial Officer | Grant or award | +4,933 | 37,945 | ||
| 2026-03-02 | Espinoza Octavio Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +23,527 | 23,527 | ||
| 2026-03-02 | Davis Todd C Chief Executive Officer | Grant or award | +10,495 | 199,381 | ||
| 2026-03-02 | Davis Todd C Chief Executive Officer | Grant or award · Employee Stock Option (right to buy) | +50,058 | 50,058 |
Page 10 of 43 · 858 trades